Global consulting firm InVentiv Health has struck a partnership with the social analytics startup Medikly, believing that young company's technology gives it an edge in assisting its clients with finding physicians to participate in clinical research.
The endorsement comes as San Francisco-based Rock Health announces a new class of 11 startups for its accelerator program, which provides access to guidance, financing and experts to help the young operations succeed.
Investors have activated a new "crowdfunding" website for life sciences deals. Dubbed VentureHealth, the website aims to expand the number of deep-pocketed players who are actively investing in medical technology startups as some traditional sources wilt.
Later this year, the Multiple Myeloma Research Foundation and genomic software startup GenoSpace plan to launch a massive data project, called the CoMMpass study, which will follow 1,000 multiple myeloma patients over a 5-year period to help scientists understand the molecular changes underpinning the progression of the disease.
By Nick Paul Taylor The Fenwick & West analysis of life science venture capital investment in 2012 is a downbeat read. Equity investments dropped 19% and the number of first round financings fell...
A new genomics upstart has taken flight to create a new way of mobilizing personal DNA data. Miinome aims to offer a unique personal genetic marketplace, serving as a broker between peoples' genetic info and buyers of the data.
Despite some technological and initial financing feats under their belts, young software and bioinformatics outfits need to answer some key questions. For example, who pays?
The biotech landscape is covered with startup efforts with cancer drugs, but when Dr. Patrick Soon-Shiong announces one, the business world stops and listens.
Philadelphia has hatched a startup with ambitious goals for improving how investigators and companies keep in touch during clinical trials. With customers and a third version of its web-based software out the door, myClin has grown out of shared office space in Old City and moved to its own office in a nearby location, MedCity News reported.
Transparency Life Sciences picked up a win for its bet on open innovation in transforming drug development. The FDA cleared the developer's IND application to study a generic hypertension drug for a new potential use in patients with multiple sclerosis, after the startup tapped crowdsourced input from experts and patients on aspects of the clinical trial.